Giant pheochromocytoma

Feocromocitoma gigante

Pheochromocytoma is a neuroendocrine neoplasia of chromaffin cells that biosynthesizes, stores, metabolizes and secretes high concentrations of catecholamines and their metabolites. The incidence is of two to eight cases per million and is frequent in the fourth and fifth decades of life. Case presentation: a 19-year-old woman with high blood pressure in medical checkups due to a history of asthma since childhood, which is studied with biochemical analysis and abdominal CT. Surgery was taken due to the suspicion of an adrenal tumor and the neoplasm is characterized in the pathology department. Conclusions: the diagnosis of pheochromocytoma and sympathetic paragangliomas that synthesize and secrete catecholamines (adrenaline, noradrenaline and dopamine) is based on the physical examination and the analytical study; The main symptom is hypertension. The treatment is surgical with complete healing in more than 90%. Abbreviations: FC, pheochromocytoma (s); PG, paraganglioma (s).

1. Posadas Calleja JG, Ugarte Torres A, Dominguez Cherit G. Feocromocitoma. Experiencia de 15 años en una instituciñn mexicana. Med Int Mex. 2006; 22(3): 210-15.

2. Oleaga A, Goñi F. Feocromocitoma: actualizacion diagnostica y terapeutica. Endocrinol Nutr. 2008; 55(5):202-16.

3. Martos-Moreno G, Pozo-Román J, Argente J. Tumores suprarrenales en la infancia. An Pediatr. 2013; 79(3): 187.e1–187.e16.

4. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007; 356(6):601-10.

5. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007; 3(2):92-102.

6. Chen H, Sippel R, O’Dorisio M, Vinik A, Lloyd R, Pacak K, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010; 39(6):775-83.

7. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer. 2004; 11(3):423-36.

8. Glodny B, Winde G, Herwig R, Meier A, K”uhle C, Cromme S et al. Clinical differences between benign and malignant pheochromocytomas. Endocr J. 2001; 48(2):151-9.